WallStreetZenWallStreetZen

NASDAQ: NEPH
Nephros Inc Stock

$3.72+0.18 (+5.08%)
Updated Feb 23, 2024
NEPH Price
$3.72
Fair Value Price
N/A
Market Cap
$39.00M
52 Week Low
$0.95
52 Week High
$4.04
P/E
-20.67x
P/B
4.52x
P/S
1.14x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.54M
Earnings
-$1.84M
Gross Margin
58.3%
Operating Margin
-13.55%
Profit Margin
-13.6%
Debt to Equity
0.27
Operating Cash Flow
$869k
Beta
0.7
Next Earnings
Mar 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A

NEPH Overview

Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Zen Score

Industry Average (31)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NEPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NEPH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NEPH is poor value based on its book value relative to its share price (4.52x), compared to the US Medical Instruments & Supplies industry average (3.69x)
P/B vs Industry Valuation
NEPH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NEPH due diligence checks available for Premium users.

Be the first to know about important NEPH news, forecast changes, insider trades & much more!

NEPH News

Valuation

NEPH fair value

Fair Value of NEPH stock based on Discounted Cash Flow (DCF)
Price
$3.72
Fair Value
$3.92
Undervalued by
5.16%
NEPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NEPH price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-20.67x
Industry
56.58x
Market
33.56x

NEPH price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.52x
Industry
3.69x
NEPH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NEPH's financial health

Profit margin

Revenue
$3.7M
Net Income
-$182.0k
Profit Margin
-4.9%
NEPH's Earnings (EBIT) of -$1.84M... subscribe to Premium to read more.
Interest Coverage Financials
NEPH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$10.9M
Liabilities
$2.3M
Debt to equity
0.27
NEPH's short-term assets ($8.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NEPH's short-term assets ($8.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NEPH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NEPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$562.0k
Investing
$0.0
Financing
$0.0
NEPH's operating cash flow ($869.00k)... subscribe to Premium to read more.
Debt Coverage Financials

NEPH vs Medical Stocks

TickerMarket Cap1d %P/EP/B
NEPH$39.00M+5.08%-20.67x4.52x
RVP$38.92M-2.99%-3.51x0.39x
OMIC$40.36M+5.97%-0.43x0.20x
POCI$35.66M+1.85%-19.59x3.15x
BNGO$44.28M-1.72%-0.16x0.37x

Nephros Stock FAQ

What is Nephros's quote symbol?

(NASDAQ: NEPH) Nephros trades on the NASDAQ under the ticker symbol NEPH. Nephros stock quotes can also be displayed as NASDAQ: NEPH.

If you're new to stock investing, here's how to buy Nephros stock.

What is the 52 week high and low for Nephros (NASDAQ: NEPH)?

(NASDAQ: NEPH) Nephros's 52-week high was $4.04, and its 52-week low was $0.95. It is currently -7.99% from its 52-week high and 291.58% from its 52-week low.

How much is Nephros stock worth today?

(NASDAQ: NEPH) Nephros currently has 10,484,932 outstanding shares. With Nephros stock trading at $3.72 per share, the total value of Nephros stock (market capitalization) is $39.00M.

Nephros stock was originally listed at a price of $7.05 in Aug 15, 2019. If you had invested in Nephros stock at $7.05, your return over the last 4 years would have been -47.23%, for an annualized return of -14.77% (not including any dividends or dividend reinvestments).

How much is Nephros's stock price per share?

(NASDAQ: NEPH) Nephros stock price per share is $3.72 today (as of Feb 23, 2024).

What is Nephros's Market Cap?

(NASDAQ: NEPH) Nephros's market cap is $39.00M, as of Feb 26, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Nephros's market cap is calculated by multiplying NEPH's current stock price of $3.72 by NEPH's total outstanding shares of 10,484,932.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.